Hikma Pharmaceuticals - HIK Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: GBX 2,050
  • Forecasted Upside: 4.65%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
GBX 1,959
▲ +20 (1.03%)

This chart shows the closing price for HIK by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Hikma Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HIK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HIK

Analyst Price Target is GBX 2,050
▲ +4.65% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Hikma Pharmaceuticals in the last 3 months. The average price target is GBX 2,050, with a high forecast of GBX 2,150 and a low forecast of GBX 2,000. The average price target represents a 4.65% upside from the last price of GBX 1,959.

This chart shows the closing price for HIK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 5 investment analysts is to hold stock in Hikma Pharmaceuticals. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
11/30/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
2/28/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
5/29/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
8/27/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
11/25/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
2/23/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
4/23/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
5/23/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/7/2024BarclaysReiterated RatingEqual WeightGBX 2,000
4/25/2024Berenberg BankReiterated RatingHoldGBX 2,000
4/8/2024BarclaysReiterated RatingEqual WeightGBX 2,000
2/26/2024Berenberg BankBoost TargetHoldGBX 1,960 ➝ GBX 2,000
11/13/2023Royal Bank of CanadaReiterated RatingSector PerformGBX 2,150
10/16/2023JPMorgan Chase & Co.Reiterated RatingOverweight
10/3/2023CitigroupReiterated RatingBuy
7/12/2023BarclaysBoost TargetEqual WeightGBX 1,700 ➝ GBX 1,800
5/22/2023Jefferies Financial GroupBoost TargetBuyGBX 2,080 ➝ GBX 2,125
5/3/2023BarclaysReiterated RatingEqual WeightGBX 1,700
4/12/2023Jefferies Financial GroupReiterated RatingBuyGBX 2,080
3/9/2023JPMorgan Chase & Co.Reiterated RatingOverweightGBX 2,100
3/1/2023Royal Bank of CanadaBoost TargetOutperformGBX 1,750 ➝ GBX 1,950
2/24/2023Berenberg BankBoost TargetHoldGBX 1,440 ➝ GBX 1,740
2/24/2023BarclaysBoost TargetEqual WeightGBX 1,650 ➝ GBX 1,700
2/14/2023JPMorgan Chase & Co.Reiterated RatingOverweight
1/31/2023CitigroupReiterated RatingBuyGBX 1,920
12/5/2022BarclaysReiterated RatingEqual WeightGBX 1,350
12/1/2022Berenberg BankReiterated RatingHoldGBX 1,440
11/3/2022Berenberg BankReiterated RatingHoldGBX 1,440
11/1/2022BarclaysReiterated RatingEqual WeightGBX 1,400
10/4/2022Berenberg BankReiterated RatingHoldGBX 1,440
9/30/2022BarclaysReiterated RatingEqual WeightGBX 1,750
8/31/2022BarclaysReiterated RatingEqual WeightGBX 1,750
8/11/2022JPMorgan Chase & Co.Lower TargetNeutralGBX 1,900 ➝ GBX 1,760
8/5/2022BarclaysDowngradeEqual WeightGBX 2,250 ➝ GBX 1,750
8/2/2022BarclaysReiterated RatingOverweightGBX 2,250
7/19/2022BarclaysLower TargetOverweightGBX 2,500 ➝ GBX 2,250
7/4/2022BarclaysReiterated RatingOverweightGBX 2,500
6/1/2022BarclaysReiterated RatingOverweightGBX 2,500
5/25/2022JPMorgan Chase & Co.DowngradeNeutralGBX 2,900 ➝ GBX 1,900
5/24/2022BarclaysReiterated RatingOverweightGBX 2,500
5/11/2022Morgan StanleyReiterated RatingEqual Weight
5/9/2022BarclaysReiterated RatingOverweightGBX 2,800
4/29/2022BarclaysReiterated RatingOverweightGBX 2,800
4/14/2022BarclaysReiterated RatingOverweightGBX 2,800
4/4/2022BarclaysReiterated RatingOverweightGBX 2,800
3/15/2022BarclaysReiterated RatingOverweightGBX 2,800
3/7/2022BarclaysReiterated RatingOverweightGBX 2,800
3/3/2022Morgan StanleyDowngradeEqual WeightGBX 2,800 ➝ GBX 2,300
2/21/2022BarclaysReiterated RatingOverweightGBX 2,800
2/9/2022Morgan StanleyReiterated RatingOverweight
2/9/2022BarclaysLower TargetOverweightGBX 3,000 ➝ GBX 2,800
1/24/2022BarclaysReiterated RatingOverweightGBX 7,000
1/17/2022JPMorgan Chase & Co.Reiterated RatingOverweight
1/4/2022JPMorgan Chase & Co.Reiterated RatingOverweight
12/17/2021BarclaysReiterated RatingOverweightGBX 3,000
11/4/2021BarclaysReiterated RatingOverweightGBX 3,000
11/4/2021Peel HuntReiterated RatingHoldGBX 2,460
11/4/2021Peel HuntReiterated RatingHoldGBX 2,460
11/1/2021CitigroupReiterated RatingBuyGBX 2,880
10/20/2021BarclaysBoost TargetOverweightGBX 2,900 ➝ GBX 3,000
9/2/2021BarclaysBoost TargetOverweightGBX 2,800 ➝ GBX 2,900
7/19/2021BarclaysReiterated RatingOverweightGBX 2,800
5/6/2021BarclaysReiterated RatingOverweightGBX 2,800
2/1/2021CitigroupReiterated RatingBuy
9/2/2020CitigroupReiterated RatingBuy
7/30/2020Peel HuntBoost TargetBuyGBX 2,380 ➝ GBX 2,860
7/7/2020Morgan StanleyUpgradeOverweightGBX 2,200 ➝ GBX 2,600
7/2/2020Peel HuntReiterated RatingBuy
6/23/2020Peel HuntReiterated RatingBuy
6/3/2020Peel HuntReiterated RatingBuy
5/22/2020Peel HuntReiterated RatingBuy
4/30/2020Peel HuntReiterated RatingBuy
4/28/2020BarclaysBoost TargetEqual WeightGBX 1,950 ➝ GBX 2,200
4/24/2020The Goldman Sachs GroupDowngradeNeutralGBX 2,200 ➝ GBX 2,400
4/24/2020Peel HuntReiterated RatingBuy
4/3/2020CitigroupBoost TargetBuyGBX 2,150 ➝ GBX 2,500
4/2/2020JPMorgan Chase & Co.UpgradeOverweightGBX 1,850 ➝ GBX 2,400
4/2/2020Peel HuntUpgradeBuyGBX 1,990 ➝ GBX 2,380
3/31/2020Peel HuntReiterated RatingHold
3/12/2020Jefferies Financial GroupBoost TargetBuyGBX 2,300 ➝ GBX 2,390
3/10/2020CitigroupUpgradeBuyGBX 1,980 ➝ GBX 2,150
3/5/2020Peel HuntReiterated RatingHold
3/2/2020BarclaysBoost TargetEqual weightGBX 1,900 ➝ GBX 1,950
2/28/2020JPMorgan Chase & Co.Reiterated RatingUnderweight
2/28/2020CitigroupReiterated RatingNeutral
2/24/2020Peel HuntReiterated RatingHold
2/20/2020BarclaysReiterated RatingEqual weight
2/18/2020Peel HuntReiterated RatingHold
2/17/2020CitigroupDowngradeNeutral
2/5/2020Peel HuntReiterated RatingHold
1/27/2020Peel HuntReiterated RatingHold
1/21/2020Jefferies Financial GroupLower TargetBuyGBX 2,310 ➝ GBX 2,240
1/20/2020BarclaysReiterated RatingEqual WeightGBX 1,900
1/10/2020Peel HuntReiterated RatingHold
1/6/2020JPMorgan Chase & Co.Boost TargetNeutralGBX 1,800 ➝ GBX 1,850
12/6/2019BarclaysReiterated RatingEqual weight
12/5/2019Peel HuntReiterated RatingHold
12/3/2019JPMorgan Chase & Co.Boost TargetNeutralGBX 1,700 ➝ GBX 1,800
11/27/2019Peel HuntReiterated RatingHold
11/27/2019HSBCReiterated RatingReduce
11/18/2019BarclaysReiterated RatingEqual weight
11/15/2019Jefferies Financial GroupReiterated RatingBuy
11/13/2019Morgan StanleyReiterated RatingEqual weight
11/7/2019CitigroupReiterated RatingBuy
11/4/2019Peel HuntReiterated RatingHold
9/2/2019Peel HuntReiterated RatingHold
8/20/2019BarclaysBoost TargetEqual weightGBX 1,800 ➝ GBX 1,900
8/9/2019Peel HuntReiterated RatingHoldGBX 1,870 ➝ GBX 2,050
7/29/2019Peel HuntReiterated RatingHold
7/3/2019Peel HuntReiterated RatingHold
6/18/2019JPMorgan Chase & Co.Reiterated RatingNeutralGBX 1,700
6/4/2019Peel HuntReiterated RatingHold
(Data available from 5/23/2019 forward)

News Sentiment Rating

0.82 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
10/26/2023
  • 1 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/25/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/25/2023
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/24/2024
  • 5 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/23/2024
  • 2 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/24/2024
  • 0 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/23/2024
  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/23/2024

Current Sentiment

  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Hikma Pharmaceuticals logo
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.
Read More

Today's Range

Now: GBX 1,959
Low: 1,940
High: 1,971

50 Day Range

MA: GBX 1,894.11
Low: 1,774
High: 2,028

52 Week Range

Now: GBX 1,959
Low: 1,711
High: 2,222

Volume

259,476 shs

Average Volume

403,057 shs

Market Capitalization

£4.35 billion

P/E Ratio

2,880.88

Dividend Yield

2.88%

Beta

0.44

Frequently Asked Questions

What sell-side analysts currently cover shares of Hikma Pharmaceuticals?

The following sell-side analysts have issued stock ratings on Hikma Pharmaceuticals in the last twelve months: Barclays PLC, Berenberg Bank, Citigroup Inc., JPMorgan Chase & Co., and Royal Bank of Canada.
View the latest analyst ratings for HIK.

What is the current price target for Hikma Pharmaceuticals?

3 Wall Street analysts have set twelve-month price targets for Hikma Pharmaceuticals in the last year. Their average twelve-month price target is GBX 2,050, suggesting a possible upside of 4.6%. Royal Bank of Canada has the highest price target set, predicting HIK will reach GBX 2,150 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of GBX 2,000 for Hikma Pharmaceuticals in the next year.
View the latest price targets for HIK.

What is the current consensus analyst rating for Hikma Pharmaceuticals?

Hikma Pharmaceuticals currently has 3 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in HIK, but not buy more shares or sell existing shares.
View the latest ratings for HIK.

What other companies compete with Hikma Pharmaceuticals?

How do I contact Hikma Pharmaceuticals' investor relations team?

Hikma Pharmaceuticals' physical mailing address is 1 New Burlington Place, LONDON, W1S 2HR, United Kingdom. The company's listed phone number is +44-20-73992760. The official website for Hikma Pharmaceuticals is www.hikma.com. Learn More about contacing Hikma Pharmaceuticals investor relations.